Company Symposia
Forum Auditorium
Monday, 2 July 2018
11:45 – 13:00 ► Company Symposium Merck
“How to improve ART efficiency and risk management to shorten time to live birth”
Chair: Ernesto Bosch, Valenica Spain
11:45 - 11:50 |
Welcome│Thomas D’Hooghe (Darmstadt, Germany) |
11:50 - 11:55
|
Delphi consensus paper on how specific treatment approaches can shorten TTLB│Ernesto Bosch (Valencia, Spain)
|
11:55 - 12:15
|
Optimize oocytes yield to maximize live births│Sandro Esteves (Sao Paulo, Brazil)
|
12:15 - 12:35
|
Remove risks in ART without compromising other outcomes such as live birth rate│Zi-Jiang Chen (Shandong, China)
|
12:35 - 12:55
|
Embrace Fertility Technologies to expand ART knowledge and patient’s opportunities│Marcos Meseguer (Valencia, Spain)
|
12:55 - 13:00
|
Summary and Closing remarks│Ernesto Bosch (Valencia, Spain)
|
14:00 – 15:15 ► Company Symposium Cooper Surgical - Download announcement here
Advancing Technologies For Reproductive Genetics: Where Are We Heading?
Chair: Tony Gordon, CooperGenomics
- Where Are We Now: The Challenges and Benefits of Genetics in IVF | Tony Gordon (VP Business Development, CooperGenomics)
- Next Steps in Preimplantation Genetic Testing | Santiago Munné (Co-Founder, CooperGenomics)
- CRISPR-Cas9 in Assisted Reproduction: The Science and the Ethical Challenges | Mark Hughes (Co-Founder and Chief Medical Officer, CooperGenomics)
17:00 – 18:15 ► Company Symposium Gedeon Richter - Download announcement here
“The future of cryopreservation in ART”
Chairs: Professor Dr Ariane Germeyer MD, PhD – Germany & Professor Dr Nikolaos Polyzos MD, PhD – Spain
- Freeze-all in ART: a shift in practice or still a walk on thin ice?│Professor Dr Michel De Vos MD, PhD – Belgium
- Can we optimise the reproductive outcomes of fresh and frozen embryo transfer?│Professor Dr Peter Humaidan MD, DMSc – Denmark
- How to optimise the ‘freeze-all’ procedure: for whom, when and how?│Dr Ernesto Bosch MD, PhD – Spain
Tuesday, 3 July 2018
11:45 – 13:00 ► Company Symposium Ferring - Download announcement here
The evolution of ART: A modern approach to ovarian stimulation
11:45 – 11:50 Evolution of gonadotrophin preparations for ovarian stimulation│Bart Fauser
11:50 – 12:10 AMH: The backbone to personalising ovarian stimulation│Elena Labarta
12:10 – 12:30 New insights on HP-hMG – MEGASET HR│Michael Alper
12:30 – 12:50 Follitropin delta: Ovarian stimulation with efficacy and safety at its core Jon Havelock
12:50 – 13:00 Conclusions│Bart Fauser
14:00 – 15:15 ► Company Symposium IBSA – Download announcement here
“A genic path for ART going forward”
Chairmen: Dominique de Ziegler (France) – Claus Yding Andersen (Denmark)
14.00 Welcome and introduction
14.05-14.25 Selecting one embryo for transfer: genetics at its best│Richard Scott (USA)
14.25-14.45 The pros and cons of gene editing in the human germline│Björn Heindryckx (Belgium)
14.45-15.05 Mitochondrial determinants of embryo quality│Francesco Fiorentino (Italy)
15.05-15.15 Discussion and conclusion
15.15 End of session
17:00 – 18:15 ► Company Symposium MSD - Download announcement here
Optimal Recruitment and Receptivity: Are They Mutually Exclusive?
Chair: Pedro N. Barri (Spain)
17:00 – 17:05 Welcome and Introduction│Pedro N. Barri
17:05 – 17:25 Are We in Control of Controlled Ovarian Stimulation?│Juan Antonio García Velasco
17:25 – 17:45 New Insights in Follicular Recruitment│Christophe Blockeel
17:45 – 18:05 How to Achieve a Receptive Endometrium for Fresh Embryo Transfer│Human M. Fatemi
18:05 – 18:15 Closing Remarks│Pedro N. Barri
Wednesday, 4 July 2018
08:30 – 09:45 ► Company Symposium Abbott Products Operations
“Dydrogesterone: Shining New Light on Life”
Chairmen – Herman Tournaye & Georg Griesinger
08:30 Opening│H. Tournaye
08:40 Do Progestogens Fit in the ESHRE Guidelines for Treatment of Recurrent Miscarriage│Prof. Carp
09:00 Luteal Support in ART: Could Dydrogesterone Become the New Gold Standard?│Prof. Blockeel
09:20 Immunomodulation in Early Pregnancy│Prof. Arck
09:40 Ending│G. Griesinger
09:45 Close
12:00 – 13:15 ► Company Symposium Japan A-PART & Vitrolife - Download announcement here
“How time-lapse technology can improve clinical outcome in natural and mild stimulation cycles”
Chairmen: Dr Hiroaki Yoshida (president of Japan A-PART, Sendai ART Clinic, Japan & Dr Markus Montag, ilabcomm, Germany
- Introduction to A-PART and IVF market in Japan│Dr Hiroaki Yoshida (Sendai ART Clinic, Japan)
- The role of time-lapse technology in mild/low stimulation program│Dr Keiichi Kato (Kato Ladies Clinic, Japan)
- The development and application of algorithms specific to mild/low stimulation│Dr Markus Montag (ilabcomm, Germany)
- The big picture: how traditional grading, PGS and time-lapse complement each other│Dr Cristina Hickman (British Fertility Society & Imperial College London, UK)